Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 13/12/2017
SIETES contiene 92150 citas

 
 
 1 a 20 de 1620 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
O’Donnell JK, Halpin J, Mattson CL, Goldebnberg BA, Gladden RM. Deaths involving fentanyl, fentanyl analogs, and U-47700 — 10 states, July–December 2016. Morbidity and Mortality Weekly Report 2017;66:3 de noviembre. [Ref.ID 102168]
2. Cita con resumen
Peckham AM, Fairman KA, Sclar DA. Call for increased pharmacovigilance of gabapentin. BMJ 2017;359:j5456. [Ref.ID 102156]
3.Tiene citas relacionadas Cita con resumen
Kyriacou DN. Opioid vs nonopioid acute pain management in the emergency department. JAMA 2017;318:1655-6. [Ref.ID 102136]
5.Tiene citas relacionadas Cita con resumen
O'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden M. Deaths involving fentanyl, fentanyl analogs, and U-47700 — 10 states, July–December 2016. Morbidity and Mortality Weekly Report 2017;66:1-5. [Ref.ID 102103]
6. Cita con resumen
Healy D. Antidepressants and murder: justice denied. BMJ 2017;358:j4196. [Ref.ID 102086]
7. Cita con resumen
Eiden C, Mathieu O, Donnadieu-Rigole H, Marrot C, Peyrière H. High opioids tolerance due to transmucosal fentanyl abuse. Eur J Clin Pharmacol 2017;73:1195-6. [Ref.ID 102078]
9. Cita con resumen
Morkem R, Williamson T, Patten S, Queenan JA, Wong ST, Manca D, Barber D. Trends in antidepressant prescribing to children and adolescents in Canadian primary care: A time-series analysis. Pharmacoepidemiol Drug Saf 2017;26:1093-9. [Ref.ID 102065]
10. Cita con resumen
Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H, Mauermann ML. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurology 2017:5 de septiembre. [Ref.ID 102058]
11. Cita con resumen
Anónimo. FDA Approves CAR-T therapy for treatment of childhood leukemia. DIA Daily 2017:1. [Ref.ID 102036]
12. Cita con resumen
Nugent SM, Morasco BJ, O'Neil ME, Freeman M, Low A, Kondo K, Elven C, Zakher B, Motu'apuaka M, Paynter R, Kansagara D. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med 2017;167:319-31. [Ref.ID 102022]
13. Cita con resumen
Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription opioid use, misuse, and use disorders in U.S. adults: 2015 National survey on drug use and health. Ann Intern Med 2017;167:293-301. [Ref.ID 102021]
14. Cita con resumen
Becker WC, Fiellin DA. Limited evidence, faulty reasoning, and potential for a global opioid crisis. BMJ 2017;358:j3115. [Ref.ID 102015]
16. Cita con resumen
Castelpietra G, Gobbato M, Valent F, De Vido C, Balestrieri M, Isacsson G. Antidepressant use in suicides: a case-control study from the Friuli Venezia Giulia Region, Italy, 2005–2014. Eur J Clin Pharmacol 2017;73:883-90. [Ref.ID 101995]
17. Cita con resumen
Ford BM, Tai S, Fantegrossi WE, Prather PL. Synthetic pot: not your grandfathers marijuana. Trends Pharmacol Sci 2017;38:257-76. [Ref.ID 101989]
18. Cita con resumen
Ramaekers JG. Drugs and driving research in medicinal drug development. Trends Pharmacol Sci 2017;38:319-21. [Ref.ID 101986]
19. Cita con resumen
Ebell MH. WHO downgrades status of oseltamivir. BMJ 2017;358:j3266. [Ref.ID 101981]
20. Cita con resumen
Grimaldi-Bensouda L, Nordon C, Rossignol M, Jardon V, Boss V, Warembourg F, Reynolds R, Kurz X, Rouillon F, Abenhaim L, for the PROTECT-WP6 study group. Antiepileptic drugs and risk of suicide attempts: a case–control study exploring the impact of underlying medical conditions. Pharmacoepidemiol Drug Saf 2017;26:239-47. [Ref.ID 101953]
Seleccionar todas
 
 1 a 20 de 1620 siguiente >>